Kristina Burow
Managing Director · ARCH Venture Partners
Managing Director
Kristina Burow is a Managing Director at ARCH Venture Partners, shaping the firm's life sciences strategy since joining in 2002, focused on company creation and development of transformative therapies. She is a co-founder and director of Neumora Therapeutics and a director of Scholar Rock, Boundless Bio and Mirador Therapeutics, among others.
Board seats
1310 current
· PUBLIC SOURCES
Credited hits
6
· PUBLIC SOURCES
Midas years
LAST CHECKED NOV 2026
Founder rating
LAST CHECKED NOV 2026
Maintained from public sources. Not claimed. If you're Kristina Burow, you can claim this profile.
Claim this profileHow claiming worksClaiming verifies identity and affiliation. It does not permit editing reviews, scores, or cited facts.
Track record
- Receptosacquired
Co-founded and served as a director of Receptos, acquired by Celgene, per her ARCH bio.
Source: archventure.com
- Orbital Therapeuticsacquired
Co-founded and served as a director of Orbital Therapeutics, acquired by Bristol Myers Squibb, per her ARCH bio.
Source: archventure.com
- Vividion Therapeuticsacquired
Co-founded and served as a director of Vividion Therapeutics, acquired by Bayer, per her ARCH bio.
Source: archventure.com
- Metseraacquired
Co-founded and served as a director of Metsera, acquired by Pfizer, per her ARCH bio.
Source: archventure.com
- Kythera Biopharmaceuticalsacquired
ARCH investment she participated in; Kythera was acquired by Allergan, per her ARCH bio.
Source: archventure.com
- Ikariaacquired
ARCH investment she participated in; Ikaria was acquired by Mallinckrodt, per her ARCH bio.
Source: archventure.com
Board seats
Current board seats · 10
- Neumora TherapeuticsSource: archventure.com
- Scholar RockSource: archventure.com
- Boundless BioSource: archventure.com
- Mirador TherapeuticsSource: archventure.com
- Architect TherapeuticsSource: archventure.com
- Autobahn TherapeuticsSource: archventure.com
- Pretzel TherapeuticsSource: archventure.com
- Tenvie TherapeuticsSource: archventure.com
- Treeline BiosciencesSource: archventure.com
- Magnet BiomedicineSource: archventure.com
Former board seats · 3
- Beam TherapeuticsSource: archventure.com
- Gossamer BioSource: archventure.com
- Vir BiotechnologySource: archventure.com
Success signals
Forbes Midas List
No public record
Not listed.
Reputation
No reputation score — basis not established for this investor.
No reputation sources on file yet.
Suggest a sourceContact
Published sources only
Published contact details collected from public sources. Not a referral, and not an introduction.
Published contact
- Website
- www.archventure.com
Published sources only
GlassVC lists only contact information the firm or its sources have published. We do not list personal emails, direct lines, or private addresses.
Claimed profiles can replace or remove contact details.
What founders say
Founder-submitted · Verified identity and relationship
No founder reviews yet
Be the first founder to share your experience with Kristina Burow. Reviews come from founders whose identity and relationship have been verified.
Write the first reviewFirm-level reviews are not attributed to Kristina Burow.
Methodology
This profile carries no tier: tier belongs to the firm and is shown only via the linked firm name — never inherited onto a person.
Credited deals, board seats, Midas years and reputation links are carried per investor in the catalog, each item with the public source it was credited from, linked from the sections above. Fields with no sourced record render their honest null states, and every published field traces to the catalog record listed below. Review dimension scores appear only at three or more reviews.
Corrections with a source: Suggest a correction.
Source record 1
- [1]
DATABASE · GlassVC catalog — Catalog record for Kristina Burow — provenance: GlassVC extended catalog, November 2026
↩ cites: Title · Firm · Type · Bio · Location · Focus · Credited deals · Board seats
EVERY FIGURE ON THIS PAGE IS TRACEABLE TO THE CATALOG RECORD ABOVE · LAST CHECKED NOV 2026
